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5Foreword
It is with pleasure that I present the new operating guidelines for the early-warning 
system (EWS), which I trust will assist greatly the implementation of Council Decision 
2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and 
control of new psychoactive substances.
The ﬁ rst EWS guidelines were published in 2001 and they have largely fulﬁ lled their 
purpose. However, a great deal has happened since then, in particular, Council 
Decision 2005/387/JHA has replaced the joint action of 16 June 1997 concerning the 
information exchange, risk assessment and control of new synthetic drugs. The decision 
maintains the mechanism for the rapid exchange of information established under the joint 
action but introduces stricter deadlines and broadens the scope beyond new synthetic 
drugs to include all new psychoactive substances that may pose public health and social 
threats, thus allowing European Union institutions and Member States to act on all new 
narcotic and psychotropic substances that appear on the European Union drug scene. 
The EWS guidelines have been fully redrafted in order to reﬂ ect the scope and 
deadlines stipulated by the new legal instrument and in view of the experience 
accumulated in the initial implementation of the decision, which is now in its second 
year of implementation. 
The new guidelines are the result of cooperation between the two organisations 
responsible for the EWS: EMCDDA and Europol. This cooperation was established 
already within the frame of the 1997 joint action and has been increasing ever since. 
In addition, the European Medicines Agency (EMEA) has provided valuable input, thus 
completing this multidisciplinary effort. I would like to acknowledge too the role of the 
respective networks in the Member States, both the Europol national units and the Reitox 
national focal points, which played an essential role in the preparation of the guidelines.
I am conﬁ dent that the new EWS guidelines explain clearly all steps, procedures, 
roles, responsibilities and the sequence of actions, thereby enabling all partners at 
European level to play their part in ensuring that the EWS reinforces the European 
Union’s actions to curb the use of new psychoactive substances. 
Wolfgang Götz
Director, EMCDDA
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7Preface
The purpose of these guidelines is to address the measures introduced by Council 
Decision 2005/387/JHA. They are concerned only with the ﬁ rst stage, i.e. the 
early-warning system and information exchange, and replace the earlier guidelines 
published by the EMCDDA in 2002. They should assist the Member States in 
implementing that decision and provide transparency to the entire process. However, 
there is no mandate and it is not the intention to advise Member States on the structure 
of their own national early-warning systems; that is not the concern of the EMCDDA 
and Europol so long as the Member States are able to implement the requirements 
of the decision and produce the expected outputs. Nevertheless, it is recommended 
that the national focal points (NFP) should ensure that regular liaison is maintained 
with Europol national units (ENU), forensic science and toxicology laboratories, 
government departments responsible for enacting drugs legislation, national medicines 
agencies and other drugs agencies as appropriate.
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9Abbreviations
CND Commission on Narcotic Drugs (UN)
EC European Community 
ECDD Expert Committee on Drug Dependence (WHO)
EDND European database on new drugs (EMCDDA)
EEC European Economic Community 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EMEA European Medicines Agency
ENU Europol national unit
EU European Union
Europol European Police Ofﬁ ce
EWS early-warning system
HDG Horizontal Drugs Group (JHA)
JHA justice and home affairs 
NFP national focal point
Reitox European Information Network on Drugs and Drug Addiction (EMCDDA)
UN United Nations
WHO World Health Organisation (UN)
The abbreviations (acronyms) and other details of many psychoactive substances 
(e.g. MBDB, PMMA, 2C-T-2) which appear throughout the guidelines can be found 
in the reference literature listed in the bibliography.
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Chapter 1
Introduction
From the early 1990s, many so-called ‘designer drugs’ were regularly discovered in 
the European Union. They were often psychotropic substances related to amphetamine 
and MDMA. Their appearance raised questions about possible health risks and 
the problems that could arise in international law enforcement cooperation if such 
substances were controlled in some Member States, but not in others. It was agreed 
that progress could be made by sharing information and by establishing a risk-
assessment procedure and a mechanism for their eventual EU-wide control. This led to 
the ‘joint action concerning the information exchange, risk assessment and control of 
new synthetic drugs’, which was adopted by the Council of the European Union under 
the Dutch Presidency on 16 June 1997 (OJ L 167, 25.06.1997). ‘New synthetic 
drugs’ were deﬁ ned as those that had a limited therapeutic value and were not at 
that time listed in the 1971 UN Convention on Psychotropic Substances yet, which 
posed as serious a threat to public health as the substances listed in Schedules I and 
II to that Convention. The term ‘new’ did not refer to newly invented, but rather ‘newly 
misused’; most of the drugs in question were ﬁ rst created many years ago.
The 1997 joint action introduced a three-step approach: (1) exchange of information/
early-warning system; (2) risk assessment; (3) a procedure for bringing speciﬁ c new 
synthetic drugs under control. Apart from the EMCDDA and its Scientiﬁ c Committee, 
the main players were Europol, EMEA, the Commission, the Council and the Member 
States. Norway and the acceding and candidate countries also participated in the 
early-warning system.
Under the 1997 joint action, over 30 new synthetic drugs were reported through 
the EWS (see Annex 1). Some were identiﬁ ed in biological samples, but most were 
found in police or customs seizures. However, few occurred in large amounts or were 
widespread. Most have had a limited life on the illicit market. The drugs identiﬁ ed since 
1997 have been largely phenethylamines (mostly listed in Shulgin and Shulgin, 1991), 
tryptamines (mostly listed in Shulgin and Shulgin, 1996) and, less commonly, substituted 
cathinones and aryl-piperazines. Risk assessments (see bibliography) were carried out 
on nine of them (MBDB, 4-MTA, GHB, ketamine, PMMA, TMA-2, 2C-T-2, 2C-T-7 and 
2C-I). Although neither ketamine nor GHB (γ-hydroxybutyrate) strictly qualiﬁ ed as ‘new 
am705257Int.indd 11 7/08/07 9:02:30
12
Early-warning system on new psychoactive substances: operating guidelines
synthetic drugs’, it was considered appropriate to carry out risk assessments because 
at that time there was information of misuse, but they were not under international 
control. A common feature of the remaining seven drugs was that they were often found 
as tablets marked with logos similar to those seen on ‘ecstasy’ tablets. By contrast, 
the reported tryptamines, none of which has so far been risk assessed, were more 
commonly seen as powders. Of the above nine substances, 4-MTA, PMMA, TMA-2, 2C-
T-2, 2C-T-7 and 2C-I were brought under control throughout the EU. Subsequently, GHB 
was added to Schedule IV of the 1971 UN Convention on Psychotropic Substances.
In 2002, a review of the joint action was carried out under the terms of the EU action 
plan on drugs 2000–04. Suggestions for improvements led to a process that, in 2005, 
culminated in Council Decision 2005/387/JHA, hereinafter called the ‘decision’. This was 
published in the Ofﬁ cial Journal of the European Union L 127, pages 32 to 37 on 20 May 
2005 and took effect the following day. The full text of the decision is shown in Annex II. 
The 2005 Council decision broadens the scope of, and replaces, the 1997 joint 
action, while maintaining a three-step approach (see Figure 1).
Step 1 — Information exchange/early warning
Once a new psychoactive substance is detected on the European market, Member States 
ensure that information on the manufacture, trafﬁ c and use of the drug is transmitted to 
the EMCDDA and Europol via the NFPs and ENUs. The data are also submitted by the 
EMCDDA or Europol for information to the European Commission and the European 
Medicines Agency (EMEA). Finally, if the EMCDDA and Europol consider that information 
collected on a new psychoactive substance merits an active follow up, a joint report is 
presented to the Council of the EU, the Commission and the EMEA. On the basis of this, 
a decision may be taken on whether or not to launch a risk assessment procedure.
Step 2 — Risk assessment
The Council may decide to launch a risk assessment procedure if at least a quarter of its 
members, or the European Commission, are in favour of this step. The EMCDDA’s Scientiﬁ c 
Committee — extended by additional experts from the Member States, the European 
Commission, Europol and the EMEA — assesses the possible health and social risks of the 
newly identiﬁ ed drug and the implications of placing it under control. A risk assessment 
report is presented to the Council, the Commission and the EMEA for consideration.
am705257Int.indd 12 7/08/07 9:02:30
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Step 3 — Decision making
At the initiative of the European Commission or a Member State, and on the basis of 
the risk assessment report, the Council may decide (by qualiﬁ ed majority) to adopt a 
decision deﬁ ning the drug to be subjected to control measures. Those measures and 
criminal penalties in the EU Member States are decided in line with national laws, 
which in turn comply with the UN Conventions. When psychoactive substances are 
brought within the scope of criminal law in all Member States, cooperation between 
countries on the control of these substances is enhanced. The Council decision does 
not prevent individual Member States from unilaterally introducing national control 
measures they consider appropriate once a new substance has been detected. 
It is generally accepted that all communications between the EMCDDA, Europol, 
the Member States and other players are carried out electronically. The information 
provided to the EMCDDA and Europol shall not include or refer to personal data 
and the Member States are under no obligation to provide information classiﬁ ed as 
conﬁ dential under their national law. Consequently, there should be no conﬁ dentiality 
issues with depersonalised data and classiﬁ cation will not apply to information on 
drug seizures or other occurrences of new psychoactive substances submitted to the 
EMCDDA by Member States. Although most documents produced by the EMCDDA 
and Europol will be unclassiﬁ ed, some will need to be marked ‘EU restricted’ (1) (e.g. 
joint report) until such time as the formal recipients of those documents have had an 
opportunity to take action. It is the responsibility of those submitting information to the 
EMCDDA or Europol, i.e. the NFPs and ENUs, to consider if their material qualiﬁ es 
for the classiﬁ cation ‘EU restricted’. Only the authors of documents can apply this 
classiﬁ cation. It should be recognised that a wider use of such classiﬁ cation may 
restrict the degree to which the information can be circulated and used by others.
Figure 2 shows the ﬂ ow of information in the EWS. The main stages are described in 
more detail in Chapter 3.
(1) According to classiﬁ cation of documents (Commission Decision 2001/844//EC, ECSC, Euratom) ‘EU restricted’ shall be 
applied to information and material the unauthorised disclosure of which could be disadvantageous to the interest of the 
European Union or one or more of its Member States.
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No
No
No
(*) Yes
NB: Activities carried out by the national focal points are shown in red.
(*) Depending on the national EWS arrangements direct communication between the NFP and the ENU may not
always occur.
EMCDDA
database
Use reporting
form
Use reporting
form,
progress/final
report or e-mail
New psychoactive
substance in
Member State
To Council and
Commission within a
further four weeks
EMCDDA
Member States
have six weeks to
reply
ENU Europol
EMCDDA informs
all Member States
EMCDDA and
Europol write joint
report
Questionnaire to
all Member States
First occurrence in
that Member State?
Need for a joint
report?
First occurrence in
any Member State
Council considers
need for a risk
assessment
EMCDDA annual
report on
substances found
EMCDDA annual
report on
implementation of
the decision
EMCDDA annual
report on the
drugs situation/
other publications
Consultation with
EMEA
Yes
Yes
Figure 2: Information ﬂ ows in the Reitox early-warning system
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The scope of the Council decision
Council Decision 2005/387/JHA (Annex II) retains the three parts of the former joint 
action as shown in Figure 1, but modiﬁ es the scope in a number of ways. 
Synthetic and naturally occurring substances
It is likely that new psychoactive substances will continue to be mostly synthetic 
products, but psychoactive drugs derived from natural (plant or animal) sources 
must also now be considered. A large number of naturally occurring psychoactive 
substances are known, but few are widely misused or ever come to the notice of law 
enforcement agencies. These may include substances that have been available for 
many years and are not strictly ‘new’. The deﬁ nition of a new psychoactive substance 
could also include industrial chemicals and related materials provided that they 
showed psychoactive properties and were being misused. 
The 1961 and 1971 UN Conventions
In the 1997 joint action, consideration was only given to those substances that could 
pose a comparably serious threat to public health as those already listed in Schedules 
I and II of the 1971 UN Convention on Psychotropic Substances. Under Article 2 of 
the decision, the scope is extended to substances that might be controlled under any 
schedule of the 1971 UN Convention or Schedules I, II or IV of the 1961 UN Single 
Convention on Narcotic Drugs. A consequence of this statement is that substances 
already listed in the international schedules cannot be regarded as new psychoactive 
substances.
However, Article 7.1 excludes substances from risk assessment that are ‘at an 
advanced stage of assessment within the United Nations system’. Within the UN 
system, an assessment of the medical aspects of substances in relation to their ability 
to cause dependence is carried out by the Expert Committee on Drug Dependence 
(ECDD) of the World Health Organisation (WHO). It is the responsibility of WHO 
to advise the Commission on Narcotic Drugs (CND) whether or not to include these 
substances in the schedules of the 1961 or 1971 UN Conventions. Article 5.2(e) 
am705257Int.indd 17 7/08/07 9:02:31
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of the decision requires the EMCDDA–Europol joint report to include information 
on ‘whether or not a new substance is currently under assessment, or has been 
under assessment, by the UN system’. To obtain such information, the EMCDDA has 
established cooperation with WHO’s Department of Medicines Policy and Standards, 
which prepares work of the ECDD. 
Precursor chemicals
Article 2 notes that precursor chemicals are excluded from the risk assessment and 
control mechanisms set by the decision:
This decision relates to end-products, as distinct from precursors in respect of which Council 
Regulation (EEC) No 3677/90 of 13 December 1990 laying down measures to be taken 
to discourage the diversion of certain substances to the illicit manufacture of narcotic drugs 
and psychotropic substances (2), and Regulation (EC) No 273/2004 of the European 
Parliament and of the Council of 11 February 2004 on drug precursors (3) provide for a 
Community regime.
This exclusion could also extend to substances on the European Community voluntary 
monitoring list of non-controlled chemicals (4) or indeed any other chemical used as 
a precursor in the illicit manufacture of a drug of misuse. However, it is possible that 
if such precursors were to be misused in their own right, then they could at least be 
subject to information exchange.
(2) OJ L 357, 20.12.1990, p. 1. Regulation as last amended by Commission Regulation (EC) No 1232/2002 (OJ L 180, 
10.7.2002, p. 5). 
(3) OJ L 47, 18.2.2004, p. 1.
(4) The Drugs Precursors Committee, which was set up by Article 10 of Council Regulation (EEC) No 3677/90 of 
13 December 1990, has established an informal list of chemical substances that are known to be diverted from their legitimate 
use, to be used for the production of drugs in the European Union. These chemical substances are not controlled under the 
United Nations Convention against Illicit Trafﬁ c in Narcotic Drugs and Psychotropic Substances, 1988 and hence are not 
regulated by EU legislation on the intra- or extra-Community trade in drug precursors. The substances are thus referred to as 
‘non-scheduled’ substances. The list is dynamically revised; it contains substances that have been agreed by EU Member States 
and serves as guidance for operators to be vigilant when placing these substances onto the Community market or in trade 
between the Community and third countries. Operators should be alert to the possibility of any circumstances that suggest such 
substances might be used for illicit manufacture of narcotics or psychotropic substances and inform their competent authority 
where appropriate.
am705257Int.indd 18 7/08/07 9:02:32
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Medicinal products
The preamble to the decision (indent 5) makes it clear that new psychoactive 
substances may include medicinal and veterinary products. 
The new psychoactive substances covered by this decision may include medicinal products 
as deﬁ ned in Directive 2001/82/EC of the European Parliament and of the Council of 
6 November 2001 on the Community code relating to veterinary medicinal products (5)
and in Directive 2001/83/EC of the European Parliament and of the Council of 
6 November 2001 on the Community code relating to medicinal products for human 
use (6).
However, while information may be exchanged as part of the EWS, and even a 
joint report prepared, it is intended (indent 8 of the preamble to the decision) that 
medicinal products should be excluded from subsequent control: 
Substances of established and acknowledged medical value are therefore excluded from 
control measures based on this decision. Suitable regulatory and public-health related 
measures should be taken for substances of established and acknowledged medical value 
that are being misused.
Such measures are established in relevant Community pharmaceutical legislation 
(Directive 2001/82/EC, Directive 2001/83/EC, Regulation (EC) No 726/2004, 
Commission Regulation (EC) No 1084/2003, Commission Regulation (EC) 
No 1085/2003). Regulatory measures such as changes in the product information 
(e.g. warnings, restrictions of use), suspension or withdrawal of existing marketing 
authorisations may be taken when new information (e.g. serious adverse reactions) 
impacts signiﬁ cantly on the beneﬁ t–risk balance of medicinal products. 
Although not explicitly mentioned in Article 7 of the decision, which stipulates the 
circumstances where no risk assessment is carried out, it must be assumed that 
medicinal products themselves are also excluded from risk assessment.
(5) OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive 2004/28/EC (OJ L 136, 30.4.2004, p. 58).
(6) OJ L 311, 28.11.2001, p. 67. Directive as last amended by Directive 2004/27/EC (OJ L 136 30.4.2004, p. 34).
am705257Int.indd 19 7/08/07 9:02:32
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Substances used to manufacture a medicinal product
Furthermore, Article 7.3 excludes a new psychoactive substance from risk assessment 
that is:
used to manufacture a medicinal product which has been granted a marketing authorisation; 
or… for which an application has been made for a marketing authorisation; or… for which 
a marketing authorisation has been suspended by a competent authority.
It should be noted that Article 7.3 only refers to exclusion from risk assessment and 
control measures, and does not prevent the collection of information or even the 
production of a joint report. A difﬁ culty is that it may not be obvious to Member 
States, the EMCDDA or even EMEA that a particular new psychoactive substance is 
used in the manufacture of a medicinal product. The expression ‘substance used to 
manufacture a medicinal product’ should be interpreted to include an intermediate 
in the production of an active pharmaceutical ingredient as well as an active 
pharmaceutical ingredient used to manufacture a medicinal product. 
The increased role of EMEA and its networks
Although the EMEA had some involvement in the joint action, in particular in the risk 
assessment phase, the 2005 Council decision increases this role. 
In addition to what is provided for under the pharmacovigilance systems as deﬁ ned in 
Directive 2001/82/EC and in Directive 2001/83/EC, the exchange of information 
on abused or misused psychoactive substances needs to be reinforced and appropriate 
cooperation with the European Medicines Agency (hereinafter ‘EMEA’) ensured. (Preamble, 
indent 9)
This decision establishes a mechanism for a rapid exchange of information on new 
psychoactive substances. It takes note of information on suspected adverse reactions to 
be reported under the pharmacovigilance system as established by Title IX of Directive 
2001/83/EC. (Article 1)
Member States and the EMEA shall ensure an appropriate exchange of information between 
the mechanism set up by means of this decision and the pharmacovigilance systems as 
deﬁ ned and established under Title VII of Directive 2001/82/EC and Title IX of Directive 
2001/83/EC. (Article 11)
am705257Int.indd 20 7/08/07 9:02:32
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Consequently, the EMCDDA and the EMEA agreed to establish stronger cooperation 
through the development of a mechanism of bilateral exchange of information on 
the basis of data available through the EWS set up by the decision and the EU 
pharmacovigilance system (which is designed to take note of adverse reactions 
to medicinal products). This exchange will mainly focus on available information 
on misuse of medicinal products. Electronic tools such as the existing databases 
EudraVigilance (EMEA) and the EDND (see page 26) would be used to allow a rapid 
and reliable exchange of information. 
It is generally agreed that it is the responsibility of each NFP to establish links with the 
relevant national competent authorities in their country to help ensure an appropriate 
exchange of information between the mechanism set up by the decision and the 
pharmacovigilance system at a national level.
am705257Int.indd 21 7/08/07 9:02:32
am705257Int.indd 22 7/08/07 9:02:32
23
Chapter 3
Elements of the early-warning system
Types of information
Directly related to the implementation of the decision
Primary data on new psychoactive substances
The principal objective of the EWS is to implement the ﬁ rst stage of the decision, 
namely to collect and disseminate information on the appearance of new psychoactive 
substances in Member States. To facilitate the identiﬁ cation of new psychoactive 
substances, the channels of the EWS are used to circulate technical information. This 
often comprises analytical data and spectra (e.g. gas-chromatography retention times, 
mass and nuclear magnetic resonance spectra). To a certain extent, such data are 
substitutes for reference standards of new psychoactive substances, which are often 
not available (see Chapter 5). Beyond this commitment, which is legally binding on 
Member States, there are two further, essentially voluntary, parts to the EWS as set out 
in the next section.
Beyond the scope of the decision 
Public-health related information 
Other information, beyond the scope of the decision, may also be circulated. 
Examples, which are not easily met by other Community mechanisms, may include 
health alerts on unusual adulterants, seizures or detections of uncommon scheduled 
drugs, problems with established synthetic/psychoactive drugs, or the existence of 
dosage units (tablets, etc.) containing unusually large amounts of active substance. 
These reports serve a ‘value-added’ purpose and are distributed by the EMCDDA 
and Europol to NFPs and ENUs on an ‘information only’ basis. The use to which this 
information is put depends entirely on the needs of the recipient Member States.
Miscellaneous technical and background reports for information and stimulation of the 
network may be circulated. 
am705257Int.indd 23 7/08/07 9:02:32
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Information collection 
Europol–EMCDDA reporting form
When a new psychoactive substance is identiﬁ ed for the ﬁ rst time in a Member State, 
formal notiﬁ cation through the EMCDDA–Europol reporting form (Annex III) should be 
completed by the Reitox NFP or the ENU and forwarded to the EMCDDA or Europol 
respectively. The EMCDDA and Europol will share the received forms. If this is the 
ﬁ rst report of a particular new psychoactive substance in the EU, then the EMCDDA 
and Europol will circulate the form including any accompanying analytical data to all 
NFPs, ENUs, the European Commission and the EMEA. 
Subsequent identiﬁ cations of that same new psychoactive substance in that Member 
State should be communicated by the Reitox NFPs and ENUs to the EMCDDA or 
Europol either by e-mail, by further use of the reporting form or in the progress/ﬁ nal 
report (see below). The form and speed of communication will partly depend on the 
nature of that subsequent occurrence. In this respect, the six criteria used to launch a 
joint report (Chapter 4) may prove helpful. In other words, the Member State should 
consider if the later occurrence: provides new information; represents a large seizure/
collection or shows widespread availability; shows evidence of organised crime 
involvement; shows evidence of international trafﬁ cking; shows evidence of cases of 
serious intoxication or fatalities, etc. Depending on their signiﬁ cance, these subsequent 
reports may be circulated by the EMCDDA and Europol to all NFPs and ENUs.
Reitox EWS progress and ﬁ nal reports
These should be completed at six-monthly intervals (Annex IV). The Reitox progress 
report covers the six-month period January to June; it should be submitted to the 
EMCDDA in July. The ﬁ nal report covers the 12 months January to December; it 
should be submitted to the EMCDDA in the following January. To assist Member States 
complete this form, the EMCDDA shall provide, at six-monthly intervals, an updated list 
of substances reported in the past 12 months.
Europol–EMCDDA joint report
If the preliminary information suggests that a joint report should be produced then 
further information will be requested from Member States by means of Europol 
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and EMCDDA questionnaires (Annex V). Before completing the questionnaire, the 
NFPs are advised to check the European database on new drugs (see page 26) to 
determine how much information is already known to the EMCDDA.
Active monitoring
In the situation where a joint report is not followed by a risk assessment, but concern 
about the speciﬁ c new psychoactive substance persists, the Council or the Commission 
may request that information be collected for a further period. At suitable time 
intervals, to be decided by all parties, the EMCDDA and Europol shall send the same 
questionnaires (Annex V) to Member States as were used to collect information for the 
joint report.
Longer-term monitoring
Substances that have been risk assessed shall be the subject of longer-term monitoring. 
This will involve a request that those substances should always be mentioned in the 
progress/ﬁ nal report (Annex IV) even if only a nil response is required.
Information sources at Member State level
It is a task of the Member State to ensure that its NFP and ENU provide the 
information required by the Council decision. The organisation and functioning 
of the EWS at national level is therefore a national responsibility. However, it is 
recommended that the NFP should ensure that regular liaison is maintained with 
the ENU, forensic science and toxicology laboratories, government departments 
responsible for enacting drugs legislation, national medicines agencies and other 
drugs agencies as appropriate. A list of information sources at national level could 
include, for example:
• health and care system — specialised and non-specialised treatment centres, 
hospitals’ emergency rooms, poisoning centres, psychiatric departments, outreach 
and street-work agencies, drug prevention and harm reduction establishments, 
low threshold services, drug help lines, general practitioners, etc., as well as the 
laboratory networks of the various healthcare establishments (toxicological analyses 
of specimens from deceased or living individuals, etc.);
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• law enforcement agencies — police, specialised drug units, customs, border 
guards, prosecutors’ ofﬁ ces, etc. and their laboratory networks (forensic analysis of 
seized drugs);
• national medicines agencies and the national pharmacovigilance systems;
• universities and research establishments;
• scientiﬁ c publications and grey literature in national languages;
• key informants — users (including discussion groups and forums), organisers of 
youth events (festivals, concerts, raves, etc.), owners and staff of clubs, etc.;
• media sources — printed and electronic media, the Internet, etc. 
Outputs of the EWS
At EU level, there are various outputs that use information on new psychoactive 
substances collected from Member States and the EMEA.
Europol–EMCDDA joint report 
See Chapter 4 for further details. The primary recipients of this report are the Council, 
the Commission and the EMEA.
European database on new drugs (EDND)
This database presents dynamic information on the occurrence of new psychoactive 
substances in the EU; it is available, by password access, on the EMCDDA and 
Reitox websites to EWS correspondents in the Member States and selected members 
of the national EWS networks. The main users of this information will be the EWS 
correspondents in the NFPs, the EMCDDA and Europol.
EMCDDA annual report on the state of the drugs problem in Europe 
A chapter of the annual report on the state of the drugs problem in Europe is, as 
a rule, devoted to psychotropic substances. Although primarily concerned with 
established drugs such as amphetamine and MDMA, some information is included 
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on those new psychoactive substances reported under the arrangements described in 
these guidelines. The annual report of the EMCDDA has a wide readership among 
policymakers, professionals and lay readers in the EU and beyond.
Annual report on the implementation of the decision
To ensure greater transparency in the implementation of the decision, Article 10 
stipulates:
The EMCDDA and Europol shall report annually to the European Parliament, the Council 
and the Commission on the implementation of this decision. The report will take into account 
all aspects required for an assessment of the efﬁ cacy and achievements of the system 
created by this decision. The report shall, in particular, include experience relating to 
coordination between the system set out in this decision and the pharmacovigilance system.
The EMCDDA and Europol present the annual report by the end of February of the 
following year.
Risk assessment
When a joint report has been issued, the Council and Member States may decide 
that the new psychoactive substance should be subjected to formal risk assessment as 
set out in Article 6 of the decision. The risk assessment is prepared by the EMCDDA 
and Europol and carried out under the auspices of the EMCDDA Scientiﬁ c Committee. 
This Committee establishes its own detailed risk assessment guidelines that take into 
account all factors that, according to the UN drug control conventions, would warrant 
the placing of substances under international control. The risk assessment report is 
submitted to the Commission and Council.
Summary of substances reported to Europol and the EMCDDA
A list of substances reported in the preceding year is compiled annually by the 
EMCDDA. The main users of this information will be the EWS correspondents in the 
NFPs, the EMCDDA and Europol.
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Other publications
Although a risk assessment will not be carried out on all new psychoactive substances 
reported to the EMCDDA, it is possible that, from time to time, sufﬁ cient information on 
a substance may be collected to warrant a separate technical publication. 
Detecting, tracking and understanding emerging drug trends 
In addition to its core objective, the Council decision stimulates the identiﬁ cation, 
monitoring and exchange of information on emerging trends in new uses of existing 
substances and on possible public health-related measures: a process that demands 
a different approach from the Reitox key indicators for estimating levels of drug use, 
associated problems and, consequently, responses. The EMCDDA has developed 
a practical tool — European perspective on drugs (E-POD) — to detect, track 
and understand emerging drug trends. This method aims to assess the veracity of 
accumulated information by triangulation of information from a wide range of different 
sources.
The early-warning system on new drugs has a proven capacity in responding 
proactively to new phenomena. Therefore, it should be a valuable asset and an active 
player in implementing E-POD through contributing and analysing information from 
various sources, including forensic science, toxicology, and law enforcement.
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The Europol–EMCDDA joint report
The process for launching a joint report is set out in Article 5.1 of the decision, 
namely:
Where Europol and the EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State on a new psychoactive 
substance merits the collection of further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a joint report (hereinafter the ‘joint 
report’). The joint report shall be submitted to the Council, the EMEA and the Commission.
This process divides into two stages as shown below, namely the assessment of 
existing information and the collection of further information.
Assessment of existing information
The joint report provides evidence-based advice to the Council and the Commission 
on the need to request a risk assessment. The information on a new psychoactive 
substance provided by Member States on the Europol–EMCDDA reporting form 
(Annex III), in the progress or ﬁ nal reports (Annex IV) or by less formal means will 
be assessed by the EMCDDA and Europol to determine if a joint report should be 
launched. This assessment is based on the following six criteria. The ﬁ rst three are the 
responsibility of Europol, while the remaining three fall within the competence of the 
EMCDDA. The decision to go ahead requires that the two institutions agree on the 
need for such a report.
Amount of seized material
This is based on information submitted to Europol and the EMCDDA via its ENUs and 
Reitox NFPs respectively, on the frequency, circumstances and quantities in which a 
new psychoactive substance is encountered. 
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Evidence of international trafﬁ cking
Europol assesses information, provided by Member States via their ENUs, on the total 
amount of seizures, countries of origin and destination plus various other trafﬁ cking/
modus operandi indicators on a new psychoactive substance appearing in the 
European Union.
Evidence of organised crime involvement 
Europol collects and assesses information, provided by Member States via their 
ENUs, on the suspected or known involvement of organised crime in the production, 
distribution and trafﬁ cking of a new psychoactive substance within the European 
Union. If a joint report is deemed appropriate, Europol will also request information 
on indications of violence and/or money laundering. If appropriate, and where more 
than two Member States are impacted, Europol may consider, in line with resources 
and priorities, the initiation and/or coordination of target-oriented investigations 
against an identiﬁ ed criminal group.
Toxicopharmacological properties of the new psychoactive substance or analogy 
with better-studied compounds
All available pharmacological and toxicological evidence should be considered. 
Furthermore, many of the drugs encountered in recent years have properties similar 
to those of existing scheduled drugs. There is an a priori assumption that analogous 
substances are potential candidates for control. Based on the information available, its 
experience and, if necessary in consultation with leading experts from Member States, 
the EMCDDA decides on the relevance of such analogy in each case. 
Evidence of the potential for further (rapid) spread
This point is satisﬁ ed if it is already clear that the new psychoactive substance has 
been seen in several Member States or that it is becoming widespread throughout or 
beyond Europe within a relatively short time (e.g. 6–12 months).
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Evidence of intoxication or fatalities
The ﬁ nding of a new psychoactive substance in either ante- or post-mortem samples is 
an immediate cause for concern since such analyses will often only have been carried 
out when there has been existing evidence of intoxication and a need for medical 
intervention.
Collection of further information
If there is strong evidence to support one or more of the above criteria, then the 
EMCDDA and Europol will request Member States and the EMEA to provide further 
updated information on the new psychoactive substance. The information required 
from the EMEA is set out in Article 5.3. The further information required from Member 
States will be collected by means of questionnaires sent to ENUs and NFPs (Annex V). 
Member States have six weeks to return the completed questionnaire.
The deadline for submitting the joint report is not more than four weeks after the 
date of receipt of the information from Member States and the EMEA. Europol or the 
EMCDDA, as appropriate, shall submit the report.
However, if a decision is subsequently made that a new psychoactive substance 
should be subjected to a risk assessment, then this could happen some months 
after the completion of the joint report. In this situation, it will be necessary for the 
EMCDDA and Europol to request that Member States complete an updated version of 
the questionnaires (Annex V).
The structure of the joint report
This is described in Article 5.2 and shall contain:
(a) a chemical and physical description, including the name under which the new 
psychoactive substance is known, including, if available, the scientiﬁ c name 
(International Non-proprietary Name);
(b) information on the frequency, circumstances and/or quantities in which a new 
psychoactive substance is encountered, and information on the means and methods of 
manufacture of the new psychoactive substance;
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(c) information on the involvement of organised crime in the manufacture or trafﬁ cking of the 
new psychoactive substance;
(d) a ﬁ rst indication of the risks associated with the new psychoactive substance, including 
the health and social risks, and the characteristics of users;
(e) information on whether or not the new substance is currently under assessment, or has 
been under assessment, by the UN system;
(f) the date of notiﬁ cation on the reporting form of the new psychoactive substance to the 
EMCDDA or to Europol;
(g) information on whether or not the new psychoactive substance is already subject to 
control measures at national level in a Member State; 
(h) as far as possible, information will be made available on:
(i) the chemical precursors that are known to have been used for the manufacture of the 
substance,
(ii) the mode and scope of the established or expected use of the new substance,
(iii) any other use of the new psychoactive substance and the extent of such use, the risks 
associated with this use of the new psychoactive substance, including the health and 
social risks.
Furthermore, according to Article 5.3, the EMEA shall submit the following information 
on whether in the European Union or in any Member State:
(a) the new psychoactive substance has obtained a marketing authorisation;
(b) the new psychoactive substance is the subject of an application for a marketing 
authorisation;
(c) a marketing authorisation that had been granted in respect of the new psychoactive 
substance has been suspended.
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Reference compounds
When a laboratory encounters a new psychoactive substance then, regardless of 
whether it has been seen before in another Member State, that laboratory will need 
a reference sample for absolute identiﬁ cation and quantiﬁ cation. To a certain extent 
published analytical data may help in that identiﬁ cation. The use of ‘recycled’ seized 
drugs as reference materials may be acceptable if the active constituent has been 
isolated and adequately characterised by appropriate analytical techniques.
The provision of ‘pure’ reference compounds to all laboratories in Member States 
presents a number of challenges. Thus, few of the substances listed in Annex I are 
commercially available, but custom synthesis of a single substance may be costly. 
Unless the appearance of a new psychoactive substance can be anticipated (see 
bibliography) then the only reference materials that are likely to be synthesised are 
those that have already been reported by a Member State.
It is likely that synthetic psychoactive substances, rather than plant-based material, will 
continue to be predominantly notiﬁ ed in the framework of the information exchange 
mechanism set up by the decision. The availability of reference materials (seized 
substances or reference substances) is of the utmost importance if forensic and 
toxicology laboratories are to identify new psychoactive substances, especially in 
the case of a new synthetic drug about which limited scientiﬁ c literature is available. 
However, in contrast to the exchange of samples of seized drugs, for which a 
procedure has been created at EU level by a Council decision of 28 May 2001 (7),
there is no European Union arrangement for the synthesis of reference substances. If 
a system that can successfully function in the long term is to be implemented, it will 
be important to consider how coordination can be established and how access to 
reference materials can be facilitated.
(7) The system organises the exchange of substances under control between European Union Member States. See Council Decision 
2001/419/JHA of 28 May 2001 on the transmission of samples of controlled substances, Council recommendation of 
30 March 2004 regarding guidelines for taking samples of seized drugs (2004/C 86/04) and the list of national contact 
points as referred to in Article 3(1) of the Council decision of 28 May 2001 (2002/C 253/02).
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Glossary
Council decision
In the context of these guidelines, this refers speciﬁ cally to Council Decision 
2005/387/JHA of 10 May 2005 on the information exchange, risk assessment 
and control of new psychoactive substances.
Early-warning system
The ﬁ rst part of the procedure described in Council Decision 2005/387/JHA 
(synonymous with the concept of ‘information exchange’).
Joint action
In the context of these guidelines, this refers speciﬁ cally to the Joint Action 97/396/
JHA of 16 June 1997 adopted by the Council on the basis of Article K.3 of the Treaty 
on European Union, concerning the information exchange, risk assessment and control 
of new synthetic drugs (OJ L 167, 25.6.1997, pp.1–3). It was replaced by Council 
Decision 2005/387/JHA in May 2005.
Medicinal product
A pharmaceutical preparation containing one or more active ingredients that has been 
licensed for therapeutic use in humans or animals. It may have the form of a dosage 
unit (tablet, capsule), injection solution, skin patch, etc. See Directives 2001/82/EC 
and 2001/83/EC.
New psychoactive substance
A substance, deﬁ ned by Council Decision 2005/387/JHA, which has the potential 
to be listed in any of the schedules of the United Nations 1971 Convention on 
Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.
New synthetic drug
A substance that was deﬁ ned by the earlier joint action (see above) and that had the 
potential to be listed in Schedules I or II of the United Nations 1971 Convention on 
Psychotropic Substances. The term is now obsolete within the context of current EU 
legislation.
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Precursor
A chemical substance that is used as a starting material or as an intermediate in 
the synthesis of a target substance. In EU legislation, it is restricted to those starting 
materials that can be used to manufacture certain substances listed in the United 
Nations 1971 Convention on Psychotropic Substances or the 1961 Single Convention 
on Narcotic Drugs.
Psychotropic substance
A material, which may or may not be chemically deﬁ ned, that has an effect on 
the central nervous system. Psychotropic substances are often, but not restricted to, 
stimulants and hallucinogens.
Reference sample
A material, also known as a reference standard, that can be used to calibrate 
chemical analytical equipment such that test samples can be compared with the 
reference as a means of conﬁ rming identity. Reference standards ideally should also 
allow quantitative analysis.
Risk assessment
The second part of the procedure described in Council Decision 2005/387/JHA.
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Annex I
New psychoactive substances reported to EMCDDA 
since 1997
Phenethylamines
Chemical structure of 4-MTA
Other examples include: 2C-I, 2C-D, 2C-E, 2C-H, 2C-T-2, 2C-T-4, 2C-T-7, 2C-P, 
MBDB, TMA-2, DPIA, PMMA, MDHOET and chloro-MDMA. This list excludes 
phenethylamines already in the UN 1971 Convention (e.g. 2C-B, MDMA).
Tryptamines
Chemical structure of N,N-di-n-propyltryptamine (DPT)
Other examples include: MIPT, 4-AcO-DIPT, AMT, DPT, 5-MeO-DMT, 5-MeO-AMT, 
5-MeO-DIPT, 5-MeO-T, 4-AcO-DET, 4-HO-DIPT, 5-MeO-MIPT, 5-MeO-DET, 
4-HO-DET, 5-HO-DMT, 4-HO-MIPT and 4-AcO-MIPT. This list excludes tryptamines 
already in the UN 1971 Convention (e.g. DMT, DET).
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Miscellaneous
Ketamine and γ-hydroxybutyrate (GHB)
Cathinones
Chemical structure of 3,4-methylenedioxypyrrolidinopropiophenone (MDPPP)
Other examples include: methylone (3,4-methylenedioxymethcathinone; MDMCAT), 
4-methylpyrrolidinopropiophenone (MPPP), α-pyrrolidinopropiophenone (PPP), 
4-methoxy-α-pyrrolidinopropiophenone (MOPPP) and 4-methyl-α-pyrrolidino-
hexanophenone (MPHP). This list excludes cathinones already in the UN 1971 
Convention (i.e. cathinone, methcathinone and amfepramone).
Piperazines
Chemical structure of m-chlorophenylpiperazine (mCPP)
Other examples include: 1-(4-methoxyphenyl)piperazine (MeOPP), 
1-benzyl-4-methyl-piperazine (BZMeP), m-triﬂ uoromethylphenylpiperazine (TFMPP), 
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p-ﬂ uorophenylpiperazine (pFPP) and benzylpiperazine (BZP). Aryl-piperazines 
are not listed in the UN Conventions.
NB: These lists are not exhaustive. Substances listed in Shulgin and Shulgin 
(1991 and 1996) as well as their simple derivatives and analogues are 
shown by acronyms only. Other synthetic drugs found in Europe before 1997 
included 1-phenethylamine (PEA), N-methyl-1-phenethylamine (N-Me-PEA),
4-methyl-1-phenethyl-amine (4-Me-PEA), 1-phenyl-3-butanamine, 
N-acetylamphetamine, N-hydroxyamphetamine, dimethylamphetamine 
and MDDMA.
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Council Decision 2005/387/JHA 
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(Acts adopted under Title VI of the Treaty on European Union)
COUNCIL DECISION 2005/387/JHA
of 10 May 2005
on the information exchange, risk-assessment and control of new psychoactive substances
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on European Union, and in
particular Articles 29, 31(1)(e) and 34 (2)(c) thereof,
Having regard to the proposal from the Commission,
Having regard to the opinion of the European Parliament (1),
Whereas:
(1) The particular dangers inherent in the development of
psychoactive substances require rapid action by the
Member States.
(2) When new psychoactive substances are not brought
within the scope of criminal law in all Member States,
problems may arise in cooperation between the judicial
authorities and law enforcement agencies of Member
States owing to the fact that the offence or offences in
question are not punishable under the laws of both the
requesting and the requested State.
(3) The European Union Action Plan on Drugs 2000-2004
provided for the Commission to organise an appropriate
assessment of the Joint Action of 16 June 1997
concerning the information exchange, risk assessment
and the control of new synthetic drugs (2) (herineafter
‘the Joint Action’) taking into account the external
evaluation commissioned by the European Monitoring
Centre on Drugs and Drug Addiction (hereinafter ‘the
EMCDDA’) of the early warning system. The assessment
showed that the Joint Action had fulfilled its expec-
tations. Nevertheless, the outcome of the assessment
made it clear that the Joint Action was in need of rein-
forcement and reorientation. In particular, its main
objective, the clarity of its procedures and definitions,
the transparency of its operation, and the relevance of
its scope had to be redefined. The Communication from
the Commission to the European Parliament and the
Council on the mid-term evaluation of the EU Action
Plan on Drugs (2000-2004) indicated that changes to
the legislation would be introduced in order to enhance
action against synthetic drugs. The mechanism as estab-
lished by the Joint Action should therefore be adapted.
(4) New psychoactive substances can be harmful to health.
(5) The new psychoactive substances covered by this
Decision may include medicinal products as defined in
Directive 2001/82/EC of the European Parliament and of
the Council of 6 November 2001 on the Community
Code relating to veterinary medicinal products (3) and
in Directive 2001/83/EC of the European Parliament
and of the Council of 6 November 2001 on the
Community Code relating to medicinal products for
human use (4).
(6) The information exchange under the early warning
system, established under the Joint Action, has proved
to be a valuable asset to the Member States.
(7) Nothing in this Decision should prevent Member States
from exchanging information, within the European Infor-
mation Network on Drugs and Drug Addiction (here-
inafter ‘the Reitox network’), on emerging trends in
new uses of existing psychoactive substances which
may pose a potential risk to public health, as well as
information on possible public health related measures,
in accordance with the mandate and procedures of the
EMCDDA.
(8) No deterioration of either human or veterinary health
care as a result of this Decision will be permitted.
Substances of established and acknowledged medical
value are therefore excluded from control measures
based on this Decision. Suitable regulatory and public
health related measures should be taken for substances
of established and acknowledged medical value that are
being misused.
ENL 127/32 Official Journal of the European Union 20.5.2005
(1) Opinion delivered on 13 January 2004 (not yet published in the
Official Journal).
(2) OJ L 167, 25.6.1997, p. 1.
(3) OJ L 311, 28.11.2001, p. 1. Directive as last amended by Directive
2004/28/EC (OJ L 136, 30.4.2004, p. 58).
(4) OJ L 311, 28.11.2001, p. 67. Directive as last amended by Directive
2004/27/EC (OJ L 136, 30.4.2004, p. 34).
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(9) In addition to what is provided for under the pharma-
covigilance systems as defined in Directive 2001/82/EC
and in Directive 2001/83/EC, the exchange of infor-
mation on abused or misused psychoactive substances
needs to be reinforced and appropriate cooperation
with the European Medicines Agency (hereinafter
‘EMEA’) ensured. The United Nations Commission on
Narcotic Drugs (hereinafter ‘CND’) Resolution 46/7
‘Measures to promote the exchange of information on
new patterns of drug use and on psychoactive substances
consumed’, provides a useful framework for action by the
Member States.
(10) The introduction of deadlines into every phase of the
procedure established by this Decision should guarantee
that the instrument can react swiftly and enhances its
ability to provide a quick-response mechanism.
(11) The Scientific Committee of the EMCDDA has a central
role in the assessment of the risks associated with a new
psychoactive substance, it will for the purpose of this
Decision be extended to include experts from the
Commission, Europol and the EMEA, and experts from
scientific fields not represented, or not sufficiently repre-
sented, in the Scientific Committee of the EMCDDA.
(12) The extended Scientific Committee that assesses the risks
associated with new psychoactive substances should
remain a concise technical body of experts, capable of
assessing effectively all risks associated with a new
psychoactive substance. Therefore the extended Scientific
Committee should be kept to a manageable size.
(13) Since the objectives of the proposed action, namely to
bring about an exchange of information, a risk-
assessment by a scientific committee and an EU-level
procedure for bringing notified substances under
control, cannot be sufficiently achieved by the Member
States and can therefore, by reason of the effects of the
envisaged action, be better achieved at European Union
level, the Union may adopt measures, in accordance with
the principle of subsidiarity as set out in Article 5 of the
Treaty. In accordance with the principle of propor-
tionality as set out in that Article, this Decision does
not go what is beyond what is necessary in order to
achieve those objectives
(14) In conformity with Article 34(2)(c) of the Treaty,
measures based upon this Decision can be taken by
qualified majority as these measures are necessary to
implement this Decision.
(15) This Decision respects fundamental rights and observes
the principles recognised by Article 6 of the Treaty and
reflected in the Charter of Fundamental Rights of the
European Union,
HAS DECIDED AS FOLLOWS:
Article 1
Subject matter
This Decision establishes a mechanism for a rapid exchange of
information on new psychoactive substances. It takes note of
information on suspected adverse reactions to be reported
under the pharmacovigilance system as established by Title IX
of Directive 2001/83/EC.
This Decision also provides for an assessment of the risks asso-
ciated with these new psychoactive substances in order to
permit the measures applicable in the Member States for
control of narcotic and psychotropic substances to be applied
also to new psychoactive substances.
Article 2
Scope
This Decision applies to substances not currently listed in any
of the schedules to:
(a) the 1961 United Nations Single Convention on Narcotic
Drugs, that may pose a comparable threat to public
health as the substances listed in Schedule I or II or IV
thereof, and
(b) the 1971 United Nations Convention on Psychotropic
Substances, that may pose a comparable threat to public
health as the substances listed in Schedule I or II or III or
IV thereof.
This Decision relates to end-products, as distinct from
precursors in respect of which Council Regulation (EEC) No
3677/90 of 13 December 1990 laying down measures to be
taken to discourage the diversion of certain substances to the
illicit manufacture of narcotic drugs and psychotropic
substances (1), and Regulation (EC) No 273/2004 of the
European Parliament and of the Council of 11 February 2004
on drug precursors (2) provide for a Community regime.
Article 3
Definitions
For the purpose of this Decision the following definitions shall
apply:
(a) ‘new psychoactive substance’ means a new narcotic drug or
a new psychotropic drug in pure form or in a preparation;
EN20.5.2005 Official Journal of the European Union L 127/33
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(b) ‘new narcotic drug’ means a substance in pure form or in a
preparation, that has not been scheduled under the 1961
United Nations Single Convention on Narcotic Drugs, and
that may pose a threat to public health comparable to the
substances listed in Schedule I, II or IV;
(c) ‘new psychotropic drug’ means a substance in pure form or
in a preparation that has not been scheduled under the
1971 United Nations Convention on Psychotropic
Substances, and that may pose a threat to public health
comparable to the substances listed in Schedule I, II, III
or IV;
(d) ‘marketing authorisation’ means a permission to place a
medicinal product on the market, granted by the
competent authority of a Member State, as required by
Title III of Directive 2001/83/EC (in the case of medicinal
products for human use) or Title III of Directive
2001/82/EC (in the case of veterinary medicinal products)
or a marketing authorisation granted by the European
Commission under Article 3 of Regulation (EC)
No 726/2004 of the European Parliament and of the
Council of 31 March 2004 laying down Community
procedures for the authorisation and supervision of
medicinal products for human and veterinary use and estab-
lishing a European Medicines Agency (1);
(e) ‘United Nations system’ means the World Health Organi-
sation (WHO), the Commission on Narcotic Drugs (CND)
and/or the Economic and Social Committee acting in
accordance with their respective responsibilities as
described in Article 3 of the 1961 United Nations Single
Convention on Narcotic Drugs or in Article 2 of the 1971
United Nations Convention on Psychotropic Substances;
(f) ‘preparation’ means a mixture containing a new
psychoactive substance;
(g) ‘Reporting Form’ means a structured form for notification of
a new psychoactive substance and/or of a preparation
containing a new psychoactive substance agreed between
the EMCDDA/Europol and their respective networks in the
Member States’ Reitox and the Europol National Units.
Article 4
Exchange of information
1. Each Member State shall ensure that its Europol National
Unit and its representative in the Reitox network provide infor-
mation on the manufacture, traffic and use, including supple-
mentary information on possible medical use, of new
psychoactive substances and of preparations containing new
psychoactive substances, to Europol and the EMCDDA, taking
into account the respective mandates of these two bodies.
Europol and the EMCDDA shall collect the information received
from Member States through a Reporting Form and commu-
nicate this information immediately to each other and to the
Europol National Units and the representatives of the Reitox
network of the Member States, the Commission, and to the
EMEA.
2. Should Europol and the EMCDDA consider that the infor-
mation provided by a Member State on a new psychoactive
substance does not merit the communication of information
as described in paragraph 1, they shall inform the notifying
Member State immediately thereof. Europol and the EMCDDA
shall justify their decision to the Council within six weeks.
Article 5
Joint Report
1. Where Europol and the EMCDDA, or the Council, acting
by a majority of its members, consider that the information
provided by the Member State on a new psychoactive
substance merits the collection of further information, this
information shall be collated and presented by Europol and
the EMCDDA in the form of a Joint Report (hereinafter the
‘Joint Report’). The Joint Report shall be submitted to the
Council, the EMEA and the Commission.
2. The Joint Report shall contain:
(a) a chemical and physical description, including the name
under which the new psychoactive substance is known,
including, if available, the scientific name (International
Non-proprietary Name);
(b) information on the frequency, circumstances and/or quan-
tities in which a new psychoactive substance is encountered,
and information on the means and methods of manufacture
of the new psychoactive substance;
(c) information on the involvement of organised crime in the
manufacture or trafficking of the new psychoactive
substance;
(d) a first indication of the risks associated with the new
psychoactive substance, including the health and social
risks, and the characteristics of users;
(e) information on whether or not the new substance is
currently under assessment, or has been under assessment,
by the UN system;
(f) the date of notification on the Reporting Form of the new
psychoactive substance to the EMCDDA or to Europol;
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(g) information on whether or not the new psychoactive
substance is already subject to control measures at
national level in a Member State;
(h) as far as possible, information will be made available on:
(i) the chemical precursors that are known to have been
used for the manufacture of the substance,
(ii) the mode and scope of the established or expected use
of the new substance,
(iii) any other use of the new psychoactive substance and
the extent of such use, the risks associated with this use
of the new psychoactive substance, including the health
and social risks.
3. The EMEA shall submit to Europol and the EMCDDA the
following information on whether in the European Union or in
any Member State:
(a) the new psychoactive substance has obtained a marketing
authorisation;
(b) the new psychoactive substance is the subject of an appli-
cation for a marketing authorisation;
(c) a marketing authorisation that had been granted in respect
of the new psychoactive substance has been suspended.
Where this information relates to marketing authorisations
granted by Member States, these Member States shall provide
the EMEA with this information if so requested by it.
4. Member States shall provide the details referred to under
paragraph 2 within six weeks from the date of notification on
the Reporting Form as set out in Article 4(1).
5. The Joint Report shall be submitted no more than four
weeks after the date of receipt of the information from Member
States and the EMEA. The Report shall be submitted by Europol
or the EMCDDA, as appropriate, in accordance with Article 5(1)
and (2).
Article 6
Risk assessment
1. The Council, taking into account the advice of Europol
and the EMCDDA, and acting by a majority of its members,
may request that the risks, including the health and social risks,
caused by the use of, the manufacture of, and traffic in, a new
psychoactive substance, the involvement of organised crime and
possible consequences of control measures, be assessed in
accordance with the procedure set out in paragraphs 2 to 4,
provided that at least a quarter of its members or the
Commission have informed the Council in writing that they
are in favour of such an assessment. The Member States or
the Commission shall inform the Council thereof as soon as
possible, but in any case within four weeks of receipt of the
Joint Report. The General Secretariat of the Council shall notify
this information to the EMCDDA without delay.
2. In order to carry out the assessment, the EMCDDA shall
convene a special meeting under the auspices of its Scientific
Committee. In addition, for the purpose of this meeting the
Scientific Committee may be extended by a further five
experts at most, to be designated by the Director of the
EMCDDA, acting on the advice of the Chairperson of the
Scientific Committee, chosen from a panel of experts
proposed by Member States and approved every three years
by the Management Board of the EMCDDA. Such experts will
be from scientific fields that are not represented, or not suffi-
ciently represented, in the Scientific Committee, but whose
contribution is necessary for the balanced and adequate
assessment of the possible risks, including health and social
risks. Furthermore, the Commission, Europol and the EMEA
shall each be invited to send a maximum of two experts.
3. The risk assessment shall be carried out on the basis of
information to be provided to the scientific Committee by the
Member States, the EMCDDA, Europol, the EMEA, taking into
account all factors which, according to the 1961 United Nations
Single Convention on Narcotic Drugs or the 1971 United
Nations Convention on Psychotropic Substances, would
warrant the placing of a substance under international control.
4. On completion of the risk assessment, a report (here-
inafter the ‘Risk Assessment Report’) shall be drawn up by
the Scientific Committee. The Risk Assessment Report shall
consist of an analysis of the scientific and law enforcement
information available, and shall reflect all opinions held by
the members of the Committee. The Risk Assessment Report
shall be submitted to the Commission and Council by the
chairperson of the Committee, on its behalf, within a period
of twelve weeks from the date of the notification by the General
Secretariat of the Council to the EMCDDA referred to in
paragraph 1.
The Risk Assessment Report shall include:
(a) the physical and chemical description of the new
psychoactive substance and its mechanisms of action,
including its medical value;
(b) the health risks associated with the new psychoactive
substance;
(c) the social risks associated with the new psychoactive
substance;
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(d) information on the level of involvement of organised crime
and information on seizures and/or detections by the autho-
rities, and the manufacture of the new psychoactive
substance;
(e) information on any assessment of the new psychoactive
substance in the United Nations system;
(f) where appropriate, a description of the control measures
that are applicable to the new psychoactive substance in
the Member States;
(g) options for control and the possible consequences of the
control measures, and
(h) the chemical precursors that are used for the manufacture of
the substance.
Article 7
Circumstances where no risk assessment is carried out
1. No risk assessment shall be carried out in the absence of a
Europol/EMCDDA Joint Report. Nor shall a risk assessment be
carried out where the new psychoactive substance concerned is
at an advanced stage of assessment within the United Nations
system, namely once the WHO expert committee on drug
dependence has published its critical review together with a
written recommendation, except where there is significant
new information that is relevant in the framework of this
Decision.
2. Where the new psychoactive substance has been assessed
within the United Nations system, but it has been decided not
to schedule the new psychoactive substance under the 1961
Single Convention on Narcotic Drugs or the 1971 Convention
on Psychotropic Substances, a risk assessment shall be carried
out only if there is significant new information that is relevant
in the framework of this Decision.
3. No risk assessment shall be carried out on a new
psychoactive substance if:
(a) the new psychoactive substance is used to manufacture a
medicinal product which has been granted a marketing
authorisation; or,
(b) the new psychoactive substance is used to manufacture a
medicinal product for which an application has been made
for a marketing authorisation or,
(c) the new psychoactive substance is used to manufacture a
medicinal product for which a marketing authorisation has
been suspended by a competent authority.
Where the new psychoactive substance falls into one of the
categories listed under the first subparagraph, the
Commission, on the basis of data collected by EMCDDA
and Europol, shall assess with the EMEA the need for
further action, in close cooperation with the EMCDDA
and in accordance with the mandate and procedures of
the EMEA.
The Commission shall report to the Council on the
outcome.
Article 8
Procedure for bringing specific new psychoactive
substances under control
1. Within six weeks from the date on which it received the
Risk Assessment Report, the Commission shall present to the
Council an initiative to have the new psychoactive substance
subjected to control measures. If the Commission deems it is
not necessary to present an initiative on submitting the new
psychoactive substance to control measures, within six weeks
from the date on which it received the Risk Assessment Report,
the Commission shall present a report to the Council explaining
its views.
2. Should the Commission deem it not necessary to present
an initiative on submitting the new psychoactive substance to
control measures, such an initiative may be presented to the
Council by one or more Member States, preferably not later
than six weeks from the date on which the Commission
presented its report to the Council.
3. The Council shall decide, by qualified majority and acting
on an initiative presented pursuant to paragraph 1 or 2, on the
basis of Article 34(2) (c) of the Treaty, whether to submit the
new psychoactive substance to control measures.
Article 9
Control measures taken by Member States
1. If the Council decides to submit a new psychoactive
substance to control measures, Member States shall endeavour
to take, as soon as possible, but no later than one year from the
date of that decision, the necessary measures in accordance with
their national law to submit:
(a) the new psychotropic drug to control measures and
criminal penalties as provided under their legislation by
virtue of their obligations under the 1971 United Nations
Convention on Psychotropic Substances;
(b) the new narcotic drug to control measures and criminal
penalties as provided under their legislation by virtue of
their obligations under the 1961 United Nations Single
Convention on Narcotic Drugs.
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2. Member States shall report the measures taken to both the
Council and the Commission as soon as possible after the
relevant decision has been taken. Thereafter this information
shall be communicated to the EMCDDA, Europol, the EMEA,
and the European Parliament.
3. Nothing in this Decision shall prevent a Member State
from maintaining or introducing on its territory any national
control measure it deems appropriate once a new psychoactive
substance has been identified by a Member State.
Article 10
Annual report
The EMCDDA and Europol shall report annually to the
European Parliament, the Council and the Commission on the
implementation of this Decision. The report will take into
account all aspects required for an assessment of the efficacy
and achievements of the system created by this Decision. The
Report shall, in particular, include experience relating to coor-
dination between the system set out in this Decision and the
pharmacovigilance system.
Article 11
Pharmacovigilance system
Member States and the EMEA shall ensure an appropriate
exchange of information between the mechanism set up by
means of this Decision and the pharmacovigilance systems as
defined and established under Title VII of Directive 2001/82/EC
and Title IX of Directive 2001/83/EC.
Article 12
Repeal
The Joint Action on New Synthetic Drugs of 16 June 1997 is
hereby repealed. Decisions taken by the Council based on
Article 5 of that Joint Action shall continue to be legally valid.
Article 13
Publication and taking effect
This Decision shall take effect on the day following that of its
publication in the Official Journal of the European Union.
Done at Brussels, 10 May 2005.
For the Council
The President
J. KRECKÉ
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EMCDDA–Europol reporting form 
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REPORTING FORM ON NEW
PSYCHOACTIVE DRUGS
In accordance with Council Decision 2005/387/JHA of
10 May 2005 on information exchange, risk
assessment and control of new psychoactive
substances.
This section should be filled in by Europol or EMCDDA
Transmitted by Europol Transmitted by EMCDDA
Ref. No: Date of transmission:
The following sections should be filled by the Europol national units (ENU) or Reitox
national focal points (NFP) based on the information available and their respective
competences
1. Member State:
Ref. No: Date:
Reporting authority:
ENU Reitox NFP
2. Chemical name:
Other name(s):
Street name(s):
3. Source of information (fill one or more as appropriate)
Seizure(s) Specify amount (weight, number of tablets, etc.):
Seizing authority:
Date: Place:
Biological sample(s) (1) Specify type:
Identifying authority:
Date: Place:
Collected sample(s) (2) Specify amount (weight, number of tablets, etc.):
Collecting authority:
Date: Place:
Other substances present (if more than one case, specify for which one):
Psychoactive ingredients:
Other ingredients:
(1) Biological (human) samples e.g. body fluids (urine, blood), tissues, hair, etc.
(2) Actively collected by drug monitoring systems for monitoring or research purposes.
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4. Physical description (in case of seizure/collection)
Form: powder tablet capsule liquid other (specify):
Colour:
For dosage unit: weight: diameter: shape: logo/markings:
5. Circumstances: production trafficking distribution use
6. Price: retail (per dosage unit): wholesale:
7. Chemical precursors:
8. Patterns of use:
9. Other possible uses (3):
10. Effects in man
Objectively observed:
Subjective (described by users):
11. Context of use
User group(s):
Setting(s):
Availability at consumer level:
12. Indication on possible risks
Health (individual):
Public health:
Social:
13. In case of production: large scale small scale unknown
Has any form of organised crime been detected: yes no
14. In case of trafficking: large scale small scale unknown
national international
Has any form of organised crime been detected: yes no
15. In case of distribution: large scale small scale unknown
Has any form of organised crime been detected: yes no
(3) For example, for medical, industrial, ritual, cosmetic, etc., purposes.
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Explanatory note (4)
Europol–EMCDDA reporting form for a new psychoactive drug
(In accordance with Council Decision 2005/387/JHA of 10 May 2005 on information exchange, risk
assessment and control of new psychoactive substances)
In order to increase consistency between the completed forms, the EMCDDA has been requested
by the EWS correspondents to prepare a short explanatory note specifying what is expected in
each particular section of the reporting form. The explanatory note is addressed primarily to the
Reitox national focal points (NFP). The Europol partners are not interested in having such a note
— in their view, the reporting form should be self-evident and as simple as possible in order to be
appropriate for a wide number of professionals who might be asked to complete it.
The EMCDDA and Europol have committed themselves that, as a rule, all information officially
received by the two agencies from the Member States through a reporting form should be
immediately transmitted to all partners. The only possible delay might occur in cases where the
initial information provided by the Europol national units (ENU) or focal points is incomplete, e.g.
basic information such as the name of the Member State; date of transmission or the chemical
name of the new psychoactive drug is missing. In such cases, a specific request for
completion/clarification will be made before the information is further communicated to all partners.
Each section below is numbered so as to correspond to the relevant section of the reporting form,
which, for clarity, is also copied into the document.
Introductory section
This section should be filled in by Europol or EMCDDA
Transmitted by Europol Transmitted by EMCDDA
Ref. No: Date of transmission:
The grey-coloured section below the reporting form’s header is to be filled in by Europol or
EMCDDA – please do not include any information here.
The Europol national units and/or Reitox national focal points, (NFP), based on the
information available and their respective competences, should complete to the extent
possible the remaining sections as follows:
Section 1
1. Member State:
Ref. No: Date:
Reporting authority:
ENU Reitox
Please include your country’s name (the name of the Member State is mandatory). The section
also allows you to fill in your own reference number (if applicable) and the date on which you
transmit the reporting form to the EMCDDA or Europol (the date is mandatory). The right-hand
side of this section also requires you, as a reporting authority, to identify your function as either
authority field is mandatory).
(4) The explanatory note is to be used in conjunction with the Europol–EMCDDA reporting form for a new psychoactive drug.
ENU or Reitox NFP — please check the appropriate box by clicking twice on it (the reporting
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Section 2
2. Chemical name:
Other name(s):
Street name(s):
Chemical name:
Please include only one chemical name (ideally this should be the systematic chemical name). If
you have more than one chemical name consult the laboratory that identified the substance (the
chemical name is mandatory).
In case you are not sure as to which is the systematic chemical name, enter one chemical name
here and include all other chemical names available to you under the subsection Other name(s).
Other name(s):
List only names, which have not appeared in Chemical name above. If available and possible
(according to your knowledge), enter all other names in the following order:
(i) other chemical names;
(ii) common generic/code/trivial names;
(iii) WHO’s international non-proprietary name — if possible indicate if it is a recommended or
proposed international non-proprietary name;
(iv) other non-proprietary names;
(v) trade name(s) — if possible indicate the producer and/or the country of production.
Street name(s):
If known, indicate in brackets where (country, region, city, etc.) and how the street name is used
(context); include common/code/trivial, international non-proprietary etc. names, if they are also
used as street names, even if they have already appeared in Other name(s) above.
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Section 3
3. Source of information (fill one or more as appropriate)
Seizure(s) Specify amount (weight, number of tablets, etc.):
Seizing authority:
Date: Place:
Biological sample(s) Specify type:
Identifying authority:
Date: Place:
Collected sample(s) Specify amount (weight, number of tablets, e t.c ):
Collecting authority:
Date: Place:
Other substances present (if more than one case, specify for which one):
Psychoactive ingredients:
Other ingredients:
This section presents the source of information: seizure, biological sample or collected sample —
please check the appropriate box by clicking on it twice, then add the remaining information
requested. Fill in one or more subsections as appropriate. Section 3 should be read and
understood in conjunction with the sections that follow, in particular, Sections 4, 5 and 6.
Seizure means a substance available (seized) through law enforcement activities (police,
customs, border guards, etc.). Please specify the seizing authority, location (place) and date as
well as the amount (weight, number of tablets, etc.).
Biological sample means body fluids (urine, blood, etc.) and/or specimens (tissues, hair, etc.).
Under subsection Specify type, please include the type of body fluids (urine, blood, etc.) and/or
specimens (tissues, hair, etc.). Please indicate also if the analysed material is from deceased
persons (post-mortem) or from living individuals (ante-mortem). Please include the identifying
authority, location (place) and date.
Collected sample means that the analysed material is actively collected for monitoring or
research purposes by an authorised and specifically designated national drug monitoring system.
Please specify the collecting authority, location (place) and date.
Under Other substances present please explain if other psychoactive ingredients or other
ingredients have been identified in the seized and/or biological and/or collected sample.
Section 4
4. Physical description (in case of seizure/collection)
Form: powder tablet capsule liquid other (specify):
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Colour:
Dosage unit: weight: diameter: shape: logo/markings:
The section Physical description is to be completed only in the case of seizures and/or collected
samples. Concerning the subsection Form, please check the appropriate box by clicking twice on
it. If none of the four options is applicable, use the option other to specify the form of the
seized/collected material. Furthermore, please complete the Colour subsection as precisely as
possible. Subsection Dosage unit is mainly meant to describe tablets and/or capsules.  
Section 5
5. Circumstances: production trafficking distribution use
Please check the most appropriate box by clicking twice on it. Often making the difference
between trafficking and distribution is difficult based on limited, initial information. For that reason,
the information provided here is of a rather preliminary nature so simply fill in the section to the
best of your judgement. This type of information would usually come from a law enforcement
source and should be entered in conjunction with Sections 13, 14 and 15.
Section 6
6. Price: retail (per dosage unit): wholesale:
Please check the most appropriate box by clicking twice on it. Information from users (i.e. usually
in the cases of collected samples) would typically refer to retail (per dosage unit) price.
Section 7
7. Chemical precursors:
Please include, as far as available, information on the main chemical precursors involved/identified
in the particular case of manufacture of the new psychoactive substance that is a subject of this
reporting form. If known, please indicate whether the precursors in question are commercially
available (i.e. easy to obtain). If known, indicate if the synthesis method used in the particular case
is easy or extensive and requiring sophisticated equipment. Do not include general information
available from the literature, Internet, etc.
Section 8
8. Patterns of use:
Please include, as far as available, information on the patterns of use, as follows: extent and
should be described in mg). This section should be completed in conjunction with Section 4.
Section 9
9. Other possible uses:
Please include information about other reported possible uses, for example, for medical, industrial,
ritual, cosmetic, nutritional, etc., purposes.
frequency of use, routes of administration  (e.g. oral — ingestion, sublingual; sniffing/snorting; 
inhaling; smoking; intranasal; injecting — s.c., i.m., i.v., i.p.; patches, trips, etc.); dosage (as a rule 
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Section 10
10. Effects in man
Objectively observed:
Subjective (described by users):
Please describe the onset and duration of action as well as short-term psychological or
physiological effects following the intake of the substance(s). Please, specify if the effects are
objectively observed (i.e. by a trained professional) or subjective (i.e. described by the users).
Section 11
11. Context of use
User group(s):
Setting(s):
Availability at consumer level:
Please describe the characteristics and behaviours of users and user group(s) e.g. age, gender,
social groups, behaviour associated with use; settings of use; and availability at consumer level
e.g. (perceived) ease of obtaining the drug through the Internet, friends/peers, retailers, dealers,
etc.
Section 12
12. Indication on possible risks
Health (individual):
Public health:
Social:
Please describe the individual and public health risks, e.g. reported non-fatal intoxications: hospital
emergencies, traffic accidents, etc.
.
; and/or fatalities: overdoses, direct and indirect deaths (e.g.
fatal traffic accidents, etc ); effects on non-using population, etc.; indicate if any of those occurred
in combination with other substance(s). Also, if available, provide details on toxicology.
Please describe the social risks: including social consequences and social behaviour
consequences (crime, violence, disorderly conduct, traffic offences, etc.) of users; consequences
from wholesale production (violence, involvement in organised crime and distribution); retail
market (violence, public order and nuisance implications), etc.
Sections 13, 14, 15
Information to be included in these sections would usually come from law enforcement sources
and be completed by the ENU or in cooperation with law enforcement professionals.
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Progress and ﬁ nal report
Early-warning system
Progress/final reporting form (i)
(In accordance with Council Decision 2005/387/JHA of 10 May 2005 on information
exchange, risk assessment and control of new psychoactive substances)
MEMBER STATE….………………
DATE (ii)…………………
PERIOD COVERED BY THE REPORT (iii)…………………
New psychoactive substances identified during the period covered by this report (iv)
Substance (v) Physical
description (vi)
Sample
type (vii)
No of
cases (viii)
Total
weight (ix)
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Explanatory notes
(i) Delete as appropriate to show if this is a progress or a final report.
(ii) The date refers to the date on which this report is submitted to EMCDDA.
(iii) The period covered is either January to June (progress report) or January to
December (final report).
(iv) Include all substances covered by the scope of Decision 2005/387/JHA. In
addition, provide information on those substances already submitted to risk
assessment (even if nil), i.e. GHB, Ketamine, MBDB, 4-MTA, PMMA, TMA-2,
2C-I, 2C-T-2 and 2C-T-7. The table should be expanded with extra rows as
required. Include free text following each substance to show: drug purities,
laboratory or other source of data; qualitative data; or other information as
appropriate.
(v) Use recognised acronyms/abbreviations wherever possible (e.g. MIPT, DXM,
2C-T-4). Include a reference to the PIHKAL or TIHKAL sequence number
where appropriate (e.g. PIHKAL #44).
(vi) Use the terms tablet (not pill), powder, capsule, liquid, blood, urine or other as
appropriate. If ‘other’ then explain in a footnote.
(vii) Use the following abbreviations: S = seizure (law enforcement); C = collected
sample; B = biological sample. Use a separate row for each sample type.
(viii) Number of 
(ix) Total weight means the aggregate weight of all cases for that substance (if a
powder), the total number of units (tablets, capsules) or the total volume
(liquids). Wherever possible use a consistent system (e.g. g or ml). For
biological samples enter '+' for qualitative detection or indicate concentration
(e.g. g or ml).
Developments in the functioning of the early-warning national networks
Include here any relevant issues relating to the national focal point, training,
staff changes, publications etc.
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………
Legal developments
Include here any changes in the control status of new psychoactive
substances at national level, etc.
…………………………………………………………………………………………
…………………………………………………………………………
cases means number of separate occurrences. 
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Request for further information
Information requested by Europol from the ENU 
Where a joint report is deemed appropriate, in order for Europol to fulﬁ l its 
obligations, in accordance with the requirements of Article 5.2, the following 
information will be requested from the Member States via their ENU:
1. the level of production of the new psychoactive substance in your country;
2. the level of distribution of the new psychoactive substance in your country;
3. the level of trafﬁ cking in your country, both for internal, transit or export 
purposes;
4. the number of seizures of the new psychoactive substance in your country; 
the total amount of the seizures; country of origin; details on the substance, 
including photos;
5. the role of organised crime, or criminal groups, in the production, distribution 
and trafﬁ cking of the new substance in your country;
6. any known aspect of violence and/or money laundering relating to the 
production and trafﬁ cking of the new psychoactive substance.
Information requested by the EMCDDA from the NFP
In order for the EMCDDA to produce the joint report in accordance with the 
requirements of Article 5.2, as complete as possible information is requested from 
the Reitox NFPs. The questionnaire, however, should be seen rather as a checklist of 
which only the available relevant information is to be provided. Moreover, in order to 
avoid duplication of efforts, before completing the questionnaire the NFPs are advised 
to check the EDND (see page 26) to determine how much information is already 
available with the EMCDDA. 
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Q1. The names under which the new psychoactive substance is known (Article 5.2(a) 
of the decision)
Please include where relevant and if available in the following order:
• chemical name(s);
• common, code or trivial names;
• ofﬁ cial synonyms and non-proprietary names other than international non-
proprietary names;
• trademark/trade name(s) — indicate the name of the country and the 
corresponding manufacturer;
• street names — if known indicate where and how the street name is used (region, 
context, etc.); include here common/code/trivial name, trade name, international 
non-proprietary names or non-proprietary names, in case it is used as a street name.
Q2. Information on the frequency, circumstances and/or quantities in which a new 
psychoactive substance is encountered (Article 5.2(b) of the decision)
Please include where relevant and if available in the following order:
Frequency, circumstances and/or quantities clearly identifying the source of 
information as follows: seizure, biological sample or collected sample. Please specify 
if other psychoactive ingredients or other ingredients have been identiﬁ ed in the 
seized and/or biological and/or collected sample. 
• For seizures, please specify the seizing authority, location (place) and date as 
well as the physical form (powder, liquid, tablets, capsules, etc.), colour, weight, 
number of tablets or capsules, etc. For dosage units specify the item weight (mg), 
diameter (mm), shape, logo/markings, etc. 
• For biological samples, please include the identifying authority, location (place) 
and date; include the type of body ﬂ uids (urine, blood, etc.) and/or specimens 
(tissues, hair, etc.); indicate also if the analysed material is from deceased persons 
(post-mortem) or from living individuals (ante-mortem). 
• For collected samples, please specify the collecting authority location (place) and 
date as well as the context; if possible, include all information as described in 
seizures above. 
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Q3. A ﬁ rst indication of the risks associated with the new psychoactive substance, 
including the health and social risks, and the characteristics of users 
(Article 5.2(d) of the decision)
Please include where relevant and if available in the following order:
First indication of the health and social risks associated with the substance, if 
relevant, including also in combinations with other substances. Specify the source of 
information: subjectively described by users; observed by peers, family members, etc.; 
objectively observed by health professionals; or from published literature on the new 
psychoactive substance in question or on similar substances, etc.
If possible, give details on number of cases for each condition and the timeframe:
• non-fatal intoxications involving the substance, substance-related hospital 
emergencies;
• direct deaths (overdoses); 
• indirect deaths (e.g. fatal trafﬁ c accidents);
• information on toxicity, tolerance and dependence potential.
Provide available information on:
• physical effects (positive and negative) as subjectively described by users and/or 
objectively observed;
• psychological effects (positive, negative) as subjectively described by users and/or 
objectively observed;
• route of administration, for example: oral (eat, drink, sublingual); intranasal (snort), 
inhale (sniff, smoke); injection (intravenous, intramuscular, etc.); transdermal 
(patches); etc.; 
• onset of action, duration, after-effects;
• dosage (mg), dosage units (tablets, capsules, etc.); 
• use in combination with other psychoactive substances;
• users’ knowledge about the substance, attractiveness to users;
• social and behavioural consequences for users;
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• how new psychoactive substance is marketed, who the intended users are; 
• main characteristics of the user population (age, gender, social groups, and 
behaviours associated with the use).
Q4. Information on whether or not the new psychoactive substance is already 
subject to control measures at national level in a Member State (Article 5.2(g) 
of the decision)
Please provide reference to the relevant legislation:
• under drug control legislation;
• under precursors control legislation;
• under medicinal products legislation;
• under any other type of legislation (such as licensing or registrations for trade, 
distribution, hazardous materials, chemicals, etc.). 
Q5. The chemical precursors and the means and methods that are known to have 
been used for the manufacture of the substance (Article 5.2(b) and 5.2(h) 
of the decision)
Please include any information available on the precursors and manufacture of the 
substance:
• list the precursors and indicate if they are readily available or difﬁ cult to obtain 
(e.g. already controlled, expensive, etc.); 
• explain the means and methods for manufacture, indicate whether the method of 
synthesis is easy or difﬁ cult (e.g. requires sophisticated equipment).
Q6. The mode and scope of the established or expected use of the new substance 
(Article 5.2(h) of the decision)
Please include any available information concerning:
• the patterns of use (extent, frequency, age groups, gender); include as much 
information as possible on the context of use, for example: used in private settings 
(at home); in public settings (various recreational settings such as bodybuilding 
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establishments, in parks, streets, pubs, discos, etc.); used in urban/rural areas; 
etc.;
• market or speciﬁ c demand for the substance; name by which it is sold/bought, 
which may be its own name or that of a controlled substance in place of which it is 
offered (e.g. as a legal alternative);
• the price (in euro) at street level (indicated by users, observed by professionals on 
health services, from published literature, studies, etc.);
• the perceived availability at consumer level.
Q7. Any other use of the new psychoactive substance and the extent of such use, the 
risks associated with this use of the new psychoactive substance, including the 
health and social risks (Article 5.2(h) of the decision)
Please include any available information concerning:
• any known uses of the substance as an end-product, for example, medical, 
research, industrial, cosmetic, religious, ritual, etc.; the risks associated with such 
uses;
• is the substance an active pharmaceutical ingredient of a medicinal product?
• is the substance used for synthesis (starting/intermediate material) of a medicinal 
product or an active pharmaceutical ingredient of a medicinal product? Is the 
substance a metabolite of a known medicinal product or psychoactive drug? 
Q8. Additional relevant information gathered in the investigation of the substance 
Please share analytical data, scientiﬁ c publications or web resources that you might 
have come across while preparing the above answers.
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The EMCDDA collects, analyses and disseminates objective, 
reliable and comparable information on drugs and drug 
addiction. In doing so, it provides its audiences with an 
evidence-based picture of the drug phenomenon at European 
level.
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a wide range of audiences including policymakers and their 
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